Chirag Talati, pharma analyst at Espirito Santo Securities tells CNBC-TV18 that since the company does not generate any sales from the facility, and approval of the 18 ANDAs (Abbreviated New Drug Application) were not expected until FY13, FY12 margins will remain intact.
first published: Jul 6, 2011 02:33 pm
A collection of the most-viewed Moneycontrol videos.
Nifty Stays Below 25,600 Amid Expiry-Led Volatility; Grasim, Hindalco In Focus| Closing Bell Live
Pine Labs’ Rs 3,900 Cr IPO| CEO Amrish Rau On Why The Issue Size Was Cut & The Post-IPO Gameplan
Can Nifty Claw Back Above 25,600 Or Will Sensex Expiry Cap The Upside?| Opening Bell Live
Gold ETFs vs Silver ETFs | Which One Is Your Wealth Buddy?
